Why Early RTSM Involvement Matters

Upstream clarity is one of the strongest predictors of downstream RTSM success. In this clip, the discussion centers on why early involvement from the right stakeholders can dramatically reduce risk at go‑live and throughout a study’s operational life.

Rather than treating RTSM as a standalone technology build, the conversation highlights how understanding endpoints, patient experience, drug packaging, product stability, and dosing requirements upfront helps establish a system that aligns with real‑world study mechanics. Even seemingly simple questions — those that appear straightforward during protocol development — often uncover mismatches between the written design and what sites will actually experience.

Identifying these gaps early allows teams to correct course before protocol approval, preventing the kinds of misalignments that later lead to disruptions, amendments, or supply‑chain challenges. By surfacing operational realities earlier, RTSM teams can build quality in from the very beginning, creating a smoother and more predictable path toward activation and execution.

This clip offers a practical look at how thoughtful early engagement strengthens readiness and safeguards study continuity.